New drug shows promise for controlling rare immune disorder
NCT ID NCT05063110
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the drug ITACITINIB in 35 adults with a mild form of a rare immune disease called HLH. The goal was to see if the drug could control the disease by improving symptoms within 15 days. The trial is now complete, and results will show how well the drug works for this condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULTS PATIENTS HAVING NON SEVERE HLH are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Avicenne
Bobigny, Bobigny, 93000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Suicide Gene-Equipped t cells aim to make stem cell transplants safer
- Engineered t cells with a kill switch aim to make stem cell transplants safer
- Massive study tracks hidden toll of rare immune diseases
- Could a common vitamin a drug tame a deadly immune storm?
- Gentler transplant shows promise for kids with blood diseases
- Timing is everything: new trial aims to save lives from immune storm